GlassScriptPhysician profile
David Chau
NPI 1306199328
$6,084.35
in general payments reported to CMS, 2019-2025
24 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $337 · 2021: $438 · 2022: $457 · 2023: $482 · 2024: $2,339 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956 · Entertainment: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.20 |
| Entertainment | $235.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Bausch & Lomb Americas INC. | $853.89 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $522.60 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Optos, INC. | $413.58 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $410.68 | 2020-2022 | |
| Dompe US, INC. | $406.64 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $378.43 | 2020-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $366.55 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $307.10 | 2022-2024 | Cirrus Hd-Oct |
| Lkc Technologies, INC. | $215.62 | 2023-2024 | |
| Glaukos Corporation | $214.32 | 2024-2025 | Idosetr, Ce-Marked Kxla System |
| Harrow Eye, LLC | $156.59 | 2025 | Vevye |
| Coopervision INC. | $153.14 | 2024 | Misight Contact Lens, Myday Contact Lens |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Rxsight INC | $105.62 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $94.81 | 2021 | |
| Aerie Pharmaceuticals, INC. | $90.68 | 2019 | |
| Astellas Pharma US INC | $58.43 | 2025 | Izervay |
| Shire North American Group INC | $43.51 | 2019 | |
| Notal Vision, INC. | $42.77 | 2022 | |
| Allergan, INC. | $36.17 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $28.67 | 2024 | Xdemvy |
| Sight Sciences, INC. | $26.38 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.